Amarantus Will Present At The Neurotech Investing And Partnering Conference, April 2015
Amarantus BioSciences Holdings, Inc., a biotechnology firm advancing diagnostic and therapeutic products for orphan diseases in the areas of neurology, ophthalmology, psychiatry and regenerative medicine, recently announced that Mr. Gerald E. Commissiong, CEO and President, will be presenting at the Neurotech Investing and Partnering Conference being held at the Hotel Nikko in San Francisco, CA on April 7-8, 2015.
Commissiong will be talking about the Lymphocyte Proliferation test (LymPro Test®), the Company’s proprietary Alzheimer’s blood diagnosis technology, and about the firm’s strategic plans for Amarantus Diagnostics. The session will take place from 10:30 to 11:30 a.m., Pacific Daylight Time. The discussion will be included in the Treatments for Alzheimer’s and Cognitive Disorders session, which will focus on neurodegenerative disorders and symptom improvement, disease modification and new options to diagnose such conditions accurately and earlier to improve outcomes.
The LymPro test uses lymphocyte measurements as a sort of analogy of neuronal cell dysfunction. Combined with standard of care clinical measurements, the LymPro test can provide physicians with greater confidence that an Alzheimer’s diagnosis is accurate.
More About The Neurotech Investing And Partnering Conference
The Neurotech Investing and Partnering Conference is now in its 10th edition and it is the premier investing and partnering conference for the industry in the neurotechnology field including pharmaceuticals, software, medical devices and diagnostics for the nervous system and brain.
More About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings has recently licensed a Phase 2b ready small molecule, Eltoprazine, appropriated for Parkinson’s disease, Levodopa-induced dyskinesia and adult ADHD. The company owns a worldwide exclusive license to the LymPro Test®, as previously mentioned, which was developed by Thomas Arendt from the University of Leipzig, to address Alzheimer’s disease. The company owns the intellectual rights to mesencephalic-astrocyte-derived neurotrophic factor and is also developing other products based on that factor to be developed into treatments for both brain and ophthalmic disorders. Finally, the firm also owns intellectual property suitable for the diagnosis of Parkinson’s disease (NuroPro) and the discovery of neurotrophic factors (PhenoGuard™).